Novartis To Acquire Majority Stake In Alcon
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal offers synergies with firm’s Ciba Vision affiliate and ex-U.S. marketing rights to Lucentis.
You may also be interested in...
Alcon Shareholders Reject "Inadequate" Novartis Offer
When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52 percent stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23 percent, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders
Alcon Shareholders Reject "Inadequate" Novartis Offer
When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52 percent stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23 percent, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.